0708.tbl. 112. árg. 2026

Environmental Impact of Pharmaceuticals – How can doctors lead sustainable prescribing practices?

doi 10.17992/lbl.2026.0708.901

Correspondence: Freyja Jonsdottir, freyjaj@landspitali.is

Key words: Environmental impact of pharmaceuticals, pharmaceutical use, environment, pharmaceuticals, sustainability

Medicines are the most common and, in many cases, the most effective treatment for disease. Medicine use is expected to continue to rise in the coming years, due in part to an ageing population. At the same time, knowledge of the environmental impact of pharmaceuticals has grown. *Therefore*, there is increasing discussion of the need for clinicians to take such impacts into account when selecting treatment for their patients.

The World Health Organization has proposed the One Health approach, which emphasises the interconnection between human health, animal health and the environment. According to the One Health approach, all of these dimensions must be considered in order to respond effectively to contemporary health threats. Medicines are designed to have specific effects on living organisms, and many of them withstand a wide range of environmental conditions without breaking down or losing activity. Pharmaceuticals can have adverse environmental effects in three ways: through pollution and the carbon footprint associated with their manufacture and distribution; through excretion of unchanged drug or active metabolites into the environment via urine or faeces; or through improper disposal. This article discusses the environmental impact of pharmaceuticals, their potential effects on human health, the current situation in Iceland, and measures to mitigate adverse effects and counter further deterioration.

 Figure 1: The One Health approach emphasizes the interplay and interconnections between human, animal, and environmental health. It highlights that addressing health threats requires considering how these three domains interact.

Table I: Environmentally hazardous drugs, based on the EU watch list of substances for monitoring.

Medication category

Generic name (active substance)

Antibiotics

Azithromycin

Clarithromycin

Erythromycin

Ciprofloxacin

Tetracycline

Oxytetracycline

Clindamycin

Ofloxacin

Hormones

Ethinylestradiol

Estradiol

Estrone

Psychotropic drugs

Fluoxetine

Venlafaxine

Cardiovascular drugs

Propranolol

Analgesics

Diklofenac

Antidiabetic drugs

Metformin

Guanylurea



Þetta vefsvæði byggir á Eplica